Shares of Eli Lilly (LLY) soared 14.3% on April 17 after data from a late-stage study showed that orforglipron achieved the primary goal of significantly reducing A1C levels compared to placebo at 40 weeks, with an average A1C reduction of 1.3% to 1.6% from a baseline of 8%. LLY's orforglipron is an investigational, once- daily small-molecule oral GLP-1 receptor agonist that can be administered at any time of the day without restrictions on food and water intake. The phase III ACHIEVE-1 study, the first of ...